INT44015

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 1983
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 16
Total Number 16
Disease Relevance 5.92
Pain Relevance 3.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Cd86)
Anatomy Link Frequency
CD86 8
B cells 1
B27M2 1
T-cells 1
Cd86 (Mus musculus)
Pain Link Frequency Relevance Heat
Etanercept 34 100.00 Very High Very High Very High
abatacept 56 99.96 Very High Very High Very High
Infliximab 35 99.48 Very High Very High Very High
Adalimumab 8 99.16 Very High Very High Very High
Neuritis 6 97.00 Very High Very High Very High
rheumatoid arthritis 123 96.40 Very High Very High Very High
Demyelination 1 92.52 High High
Sciatic nerve 2 91.28 High High
Inflammation 55 88.56 High High
Potency 6 86.44 High High
Disease Link Frequency Relevance Heat
Apoptosis 74 98.76 Very High Very High Very High
Experimental Autoimmune Neuritis 6 97.00 Very High Very High Very High
Rheumatoid Arthritis 123 96.40 Very High Very High Very High
Death 26 96.32 Very High Very High Very High
Demyelinating Disease 2 92.52 High High
Disease 447 89.84 High High
INFLAMMATION 63 88.56 High High
General Immunology 9 88.56 High High
Immunization 9 84.00 Quite High
Systemic Lupus Erythematosus 53 82.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The same researchers also demonstrated that CTLA4Ig, an immunoglobulin shown to block the interaction of CD80 and CD86 ligands on antigen-presenting cells with CTLA4 receptors on T-cells, appeared to stabilize the expression of adenovirus in the TM [8].
CD86 Binding (interaction) of in T-cells
1) Confidence 0.31 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2267727 Disease Relevance 0.11 Pain Relevance 0
Meanwhile, the co-stimulatory molecules CD40 and CD86 were also upregulated by E2 and CpG separately or together, but the effect of E2 on CD80 expression was minimal compared with CD40 and CD86.
CD86 Binding (minimal) of in CD86
2) Confidence 0.27 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793013 Disease Relevance 0.28 Pain Relevance 0
Cross-reactivity with B7 is attributed to a B27-like epitope on the B7 antigen but which, as determined by cytotoxicity blocking studies, is distinct from the B7 allospecific epitope itself.
B7 Binding (Cross-reactivity) of
3) Confidence 0.26 Published 1983 Journal Br. J. Rheumatol. Section Abstract Doc Link 6360285 Disease Relevance 0.09 Pain Relevance 0
Belatacept, currently enrolling phase III trials in renal transplantation, was rationally designed from abatacept to bind with more avidity to CD86, providing the more potent immunosuppressive properties required for immunosuppression in transplantation.
CD86 Binding (bind) of in CD86 associated with abatacept
4) Confidence 0.26 Published 2007 Journal Annu. Rev. Med. Section Abstract Doc Link 17020493 Disease Relevance 0.33 Pain Relevance 0.35
The second B27 monoclonal antibody, B27M2, is a lymphocytotoxic IgM antibody reacting with most (greater than 85%) but not all of B27 antigens tested and having no cross-reactivity with B7.
B7 Binding (reactivity) of in B27M2
5) Confidence 0.25 Published 1983 Journal Br. J. Rheumatol. Section Abstract Doc Link 6360285 Disease Relevance 0.13 Pain Relevance 0
Ligands for ICOS are constitutively expressed on APCs and, in contrast to CD80 and CD86, do not underlie the control of CD40 or signals involving the NF-?
CD86 Binding (contrast) of in CD86
6) Confidence 0.20 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582810 Disease Relevance 0.34 Pain Relevance 0.08
Evidently, CD28 is required for interaction with B7 to regulate the activation of T and B cells that initiates development of EAN.
B7 Binding (interaction) of in B cells associated with neuritis
7) Confidence 0.19 Published 2001 Journal J. Neuroimmunol. Section Abstract Doc Link 11240022 Disease Relevance 0.92 Pain Relevance 0.63
The selective costimulation modulator abatacept (CTLA-4Ig) binds to CD80 and CD86, blocking interaction with CD28, and is approved for the treatment of moderate to severe rheumatoid arthritis.
CD86 Binding (binds) of in CD86 associated with rheumatoid arthritis and abatacept
8) Confidence 0.19 Published 2007 Journal Annu. Rev. Med. Section Abstract Doc Link 17020493 Disease Relevance 0.33 Pain Relevance 0.33
The best way to inhibit CD28-CD80/CD86 interaction is by means of cytotoxic T-lymphocyte antigen (CTLA)4-immunoglobulin (Ig).
CD86 Binding (interaction) of in CD86
9) Confidence 0.19 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582810 Disease Relevance 0.13 Pain Relevance 0.13
It has been less effective in transplantation models, but recent data from a nonhuman primate model [9] indicate that a mutated abatacept - namely belatacept, which binds CD86 with greater affinity - has promising effects.
CD86 Binding (binds) of in CD86 associated with abatacept
10) Confidence 0.19 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582810 Disease Relevance 0.18 Pain Relevance 0.28
One of these fusion proteins, abatacept, binds CD80 more avidly than CD86.
CD86 Binding (binds) of in CD86 associated with abatacept
11) Confidence 0.18 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833980 Disease Relevance 0.37 Pain Relevance 0.29
It selectively modulates the co-stimulatory pathway of T-cell activation by preventing the engagement of CD80/CD86 on APCs with CD28 on T cells.
CD86 Binding (engagement) of in CD86
12) Confidence 0.12 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582809 Disease Relevance 0.46 Pain Relevance 0.53
ETC has been recognized as an early characteristic of apoptotic
ETC Binding (recognized) of associated with apoptosis
13) Confidence 0.02 Published 2006 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1559913 Disease Relevance 0.74 Pain Relevance 0.04
and the iron-sulfur centers of ETC at complexes 1, 2, and 3,
ETC Binding (complexes) of
14) Confidence 0.02 Published 2006 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1559913 Disease Relevance 0.40 Pain Relevance 0.06
and the iron-sulfur centers of ETC at complexes 1, 2, and 3,
ETC Binding (centers) of
15) Confidence 0.02 Published 2006 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1559913 Disease Relevance 0.34 Pain Relevance 0.06
 ; however, membrane-bound TNF is not, or less, recognized by ETC 28, whereas IFX and ADA also bind to this uncleaved form.
ETC Binding (recognized) of associated with infliximab, adalimumab and etanercept
16) Confidence 0.01 Published 2008 Journal International Journal of Medical Sciences Section Body Doc Link PMC2452978 Disease Relevance 0.79 Pain Relevance 0.79

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox